Eli M. Roth

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 700 citations · Full text

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

Eli M. Roth, James M. McKenney, Corinne Hanotin et al. · New England Journal of Medicine · 2012 · 462 citations · Full text

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

Eli M. Roth, Marja‐Riitta Taskinen, Henry N. Ginsberg et al. · International Journal of Cardiology · 2014 · 248 citations · Full text

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

Daniel Gaudet, Dean J. Kereiakes, James M. McKenney et al. · The American Journal of Cardiology · 2014 · 209 citations

Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management

Eric J. Dippel, Dean J. Kereiakes, Daniel A. Tramuta et al. · Catheterization and Cardiovascular Interventions · 2001 · 135 citations

Heart Failure, Coronary Artery Perforation, Coronary Artery Disease +22